Home/Filings/4/0000950170-25-085378
4//SEC Filing

DENNER ALEXANDER J 4

Accession 0000950170-25-085378

CIK 0001446847other

Filed

Jun 11, 8:00 PM ET

Accepted

Jun 12, 4:17 PM ET

Size

8.0 KB

Accession

0000950170-25-085378

Insider Transaction Report

Form 4
Period: 2025-06-10
Transactions
  • Award

    Class A Common Stock

    2025-06-10+45,000211,769 total
Holdings
  • Class A Common Stock

    (indirect: See Footnote)
    16,390,000
Denner Alexander J
Director10% Owner
Transactions
  • Award

    Class A Common Stock

    2025-06-10+45,000211,769 total
Holdings
  • Class A Common Stock

    (indirect: See Footnote)
    16,390,000
Footnotes (2)
  • [F1]The restricted stock, granted pursuant to the Second Amended and Restated Non-employee Director Compensation Policy, effective January 1, 2024, vests in full on the date immediately preceding the date of the annual meeting of stockholders for the next calendar year.
  • [F2]Consists of shares that are held by Sarissa Capital Management LP ("Sarissa Capital") or by the funds and other investment vehicles (the "Sarissa Funds") for which Sarissa Capital serves as investment advisor. Dr. Denner is the Chief Investment Officer of Sarissa Capital and the managing member, general partner or other control party of the Sarissa Funds. By virtue of the foregoing, Dr. Denner may be deemed to indirectly beneficially own the shares that these funds directly beneficially own. Each of Sarissa Capital, the Sarissa Funds and Dr. Denner disclaims beneficial ownership of these shares except, in each case, to the extent of their pecuniary interest therein.

Documents

1 file

Issuer

IRONWOOD PHARMACEUTICALS INC

CIK 0001446847

Entity typeother

Related Parties

1
  • filerCIK 0001361754

Filing Metadata

Form type
4
Filed
Jun 11, 8:00 PM ET
Accepted
Jun 12, 4:17 PM ET
Size
8.0 KB